Share Name Share Symbol Market Type Share ISIN Share Description
Akers Biosciences, Inc LSE:AKR London Ordinary Share US00973E1029 COM SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 235.00p 220.00p 250.00p 235.00p 235.00p 235.00p 3,051 07:58:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 1.4 -6.5 -122.8 - 12.77

Akers Biosciences (AKR) Latest News

More Akers Biosciences News
Akers Biosciences Takeover Rumours

Akers Biosciences (AKR) Share Charts

1 Year Akers Biosciences Chart

1 Year Akers Biosciences Chart

1 Month Akers Biosciences Chart

1 Month Akers Biosciences Chart

Intraday Akers Biosciences Chart

Intraday Akers Biosciences Chart

Akers Biosciences (AKR) Discussions and Chat

Akers Biosciences Forums and Chat

Date Time Title Posts
30/8/201615:07Akers Biosciences Inc 20113,261
24/8/201508:47Akers biosciences229
05/9/201413:48Reasons to BUY in Akers Bioscience (AKR)-
01/9/201320:40FDR Aprrobval due to today4
14/1/201100:33Akers Biosciences Inc - 2010 Thread54

Add a New Thread

Akers Biosciences (AKR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:24:02220.003,0006,600.00O
09:28:01220.0051112.20O
View all Akers Biosciences trades in real-time

Akers Biosciences (AKR) Top Chat Posts

DateSubject
27/9/2016
09:20
Akers Biosciences Daily Update: Akers Biosciences, Inc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AKR. The last closing price for Akers Biosciences was 235p.
Akers Biosciences, Inc has a 4 week average price of 241.75p and a 12 week average price of 227.42p.
The 1 year high share price is 242.50p while the 1 year low share price is currently 82.50p.
There are currently 5,434,212 shares in issue and the average daily traded volume is 2,238 shares. The market capitalisation of Akers Biosciences, Inc is £12,770,398.20.
30/6/2016
11:21
rivaldo: The UK share price is still behind last night's close in the USA of $2.78. I agree that after this news is announced in the USA this afternoon things could get extremely interesting over there.
30/6/2016
07:19
rivaldo: Wow - AKR announce the "highly successful" completion of a trial for "the first rapid test for Chlamydia diagnosis using a finger stick blood sample": Http://www.investegate.co.uk/akers-biosciences--akr-/rns/clinical-trial-for-rapid-chlamydia-test-completed/201606300700097101C/ Imagine the potential for this test and the potential global take-up.... There's certainly nothing in the share price for this on a mere £9m m/cap.
29/2/2016
15:05
mcmather: btw share price on nasdaq of US$1.64 = £1.17 approx. A share price on nasdaq of US$1.72 = £1.23 approx.
18/8/2015
09:13
mcmather: 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN
05/8/2015
22:44
mcmather: Depends whether you are including the below in the "us" bit? 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN Good luck wolfie and waylander by the way.
16/7/2015
23:34
mcmather: This from around 2008/09: Rep. Rob Andrews (NJ-1) requests $20,000,000 for: Akers Biosciences Inc. 201 Grove Road Thorofare, NJ 08086. hTtps://washingtonwatch.com/bills/show/ED_8072.html This from 30 June 2015: In addition, Mr. Andrews was appointed to the Company's Governance and Nominating Committee, Compensation Committee and Audit Committee; and will serve as the Chairman of the Company's Compensation Committee. Anyone guess where this is going?? This from the heading: 9 January 2015 - Greedy incompetents or citizens the US should be rightly proud of? Discussion welcome on the thread. 23 July 2013 - Dr Raymond Akers disposes of 7m shares; roughly £140,000. 8 August 2013 - Proposed Nasdaq listing. 18 November 2013 - Share consolidation; 156/1. 23 January 2014 - Listing opens on Nasdaq. 14 May 2014 - Q1 2014 results - Net loss $595,600 mainly due to costs associated with NASDAQ IPO. 12 August 2014 - Q2 2014 results - Net loss $494,995 Three factors contributed to the increased loss: maintaining dual listings of our stock has significantly increased costs associated with compliance with regulatory requirements, the expansion of sales and marketing efforts and stock option based compensation for our directors, officers and key employees. 13 November 2014 - Q3 2014 results - Net loss $1,124,320 as a result of hiring additional personnel, capital market commitments and marketing activities. 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN
09/3/2015
17:56
mcmather: Norbus, re Dr Raymond Akers Jnr's 'activities' here, I'd suspect that there are one or two - perhaps quite a few more? - paying close attention to all ongoing including this from an earlier post on here: $650,000 for a company which will later announce massive losses for 2014; his remuneration package will equate to around 14.5% of all (gross, not net) revenue generated by the company in 2014. As the heading asks: 9 January 2015 - Greedy incompetents or citizens the US should be rightly proud of? Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) The Mail Online appears to have 100m unique hits / visitors per month and this fella tipped them as his share for 2015: Ian Lyall - Akers Bioscience If you look at the share price chart of Akers Bioscience you’d think it hadn’t been a particularly clever year for the diagnostics company. http://www.thisismoney.co.uk/money/investing/article-2890431/Shares-vote-2015-Daily-Mail-s-City-reporters-reveal-market-tips.html#ixzz3Tubf4INL
19/2/2015
09:27
mcmather: I'd take hope out of the equation; based upon what you know do you think Dr Raymond Akers Jr is more concerned about the return on investment of shareholders - of the company which bears his name - both here and in his native United States of America? Or more concerned about his remuneration package which, with the shares he has very recently awarded to himself, will take his latest package to nearly $650,000?!? $650,000 for a company which will later announce massive losses for 2014; his remuneration package will equate to around 14.5% of all (gross, not net) revenue generated by the company in 2014. As the heading asks: 9 January 2015 - Greedy incompetents or citizens the US should be rightly proud of? Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75)
15/2/2015
23:49
mcmather: Save the best till last... 24.10 I think it (the company / the current stock price) is just an absolute steal of a buy at the moment. I am so confident of this that me, Thomo', Little Tommy and our Gav' invested $674,000 in buying 180,00 shares. Sorry, what's that Maureen? I can't say that because we did NOT part with any money - least of all our own - but simply awarded them to ourselves? Crikey, thanks Maureen, I think we might just have got away with that.... 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN
23/1/2015
09:11
mcmather: The below is / was based on the figures achieved in Q1 2014: $1.2m revenue Q1 2014. X4 = $5m for 2014 if things simply remain the same each 1/4. Plus anything from: Chube - comprehensive launch in the US in 2014. Metron - comprehensive launch in the US in 2014. VIVO - comprehensive launch in the US in 2014. Chube - Poland New sales strategy in the US re the PIFA / Pluss range of products. The recent 3 year / $5m purchase order in place in Aus / UAE / Singapore / Oman. The PIFA range of products in China and the tie up with Novotek Therapeutics. The point again, has the management exceeded what it set out to do at start of 2014 / following Q1 2014 results? If the answer is no then the following persons should NOT have received the following benefits - there is NO DISCERNIBLE REASON OR JUSTIFICATION for doing so; perhaps the management would like to clearly explain to shareholders (myself included) why they have effectively given themselves $675,000 of monies that actually belongs to the entity that is the company and which therefore is owned by shareholders and persons who appear to be predominantly based both here and in the US: WHY HAVE THE BELOW RECEIVED THE FOLLOWING BENEFITS? PLEASE DISCUSS Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75)
Akers Biosciences share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20160927 20:42:55